Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

The approval of Ogivri was based on data demonstrating that the biosimilar product is highly similar to the reference product, Herceptin.

Diana Ernst, RPh

December 6, 2019

Truxima (rituximab-abbs; Teva and Celltrion), a biosimilar to Rituxan (rituximab; Genentech) will be available in the US the week of November 11, 2019 for the treatment of adults with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Diana Ernst, RPh

November 12, 2019

Cinvanti Single-Dose Regimen Approved for Patients Receiving Moderately Emetogenic Chemotherapy

Cinvanti injectable emulsion can be administered as a 2-minute intravenous injection or 30-minute intravenous infusion.

Diana Ernst, RPh

October 29, 2019